Search results
She had Parkinson's and didn't want to live. Then she got this surgery.
USA TODAY via Yahoo News· 2 days agoThen everything changed. Patients will typically follow up frequently within the first six months,...
Baird starts Praxis shares coverage with outperform, cites promising drug By Investing.com
Investing.com· 1 day ago(NASDAQ: PRAX), assigning an Outperform rating to the company's shares with a price target of $117....
Earnings call: Jazz Pharmaceuticals sustains growth with key drivers By Investing.com
Investing.com· 8 hours agoThe company has completed a Biologics License Application (BLA) for zanidatamab in the treatment of...
Does Consuming Too Many Electrolytes Cause Side Effects? Here's What Dietitians Say
Eating Well via Yahoo News· 3 days ago“That’s why it’s essential to pay attention to the signs and symptoms of overconsuming electrolytes...
Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 1 day agoThe firm views Praxis' ulixacaltamide as "a promising agent" for the treatment of essential tremor...
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Zacks via Yahoo Finance· 6 days agoSage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN...
The Herald Journal· 1 day agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug ...
'They're not alone': Longview Parkinson's support group offers education, connection
The Longview News-Journal· 2 days agoDetecting the signs and symptoms of Parkinson’s disease early is the best way for someone who has it...
Short Interest in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Expands By 77.1%
ETF DAILY NEWS· 4 days agoPraxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest ...